Tier 4 — mechanistic

α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming

Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, Di Conza G, Cheng WC, Chou CH, Vavakova M, Muret C, Debackere K, Mazzone M, Huang HD, Fendt SM, Ivanisevic J, Ho PC
Nature Immunology 2017 18(9):985-994

Bibliography

PubMed
PMID 28714978
DOI
10.1038/ni.3796
Funding
Academic and research-institute funding supported the work; full grant details are reported in the Nature Immunology article.
Competing interests
No Ca-AKG supplement manufacturer intervention was tested; consult the publication for the complete author disclosure statement.

Study snapshot

DesignMechanistic immunometabolism study using macrophage cell systems and animal experiments.
ModelMacrophage activation models examining glutaminolysis, AKG/succinate balance and epigenetic regulation.
SampleMechanistic laboratory study; no human oral supplementation cohort.
InterventionManipulation of glutamine metabolism and AKG availability during macrophage activation.
DurationAcute cell and experimental immune-activation protocols.
EndpointsM1/M2 macrophage polarization; Fatty-acid oxidation; Jmjd3-dependent epigenetic regulation; Inflammatory gene expression

What the study showed, in plain terms

This foundational immunometabolism paper showed that AKG is not merely a fuel metabolite; it can help shape macrophage phenotype through metabolic and epigenetic signaling.

Higher AKG availability favored alternative M2-type activation through fatty-acid oxidation and Jmjd3-dependent epigenetic reprogramming, while the AKG-to-succinate balance influenced inflammatory phenotype.

It supports a plausible inflammation mechanism but does not show that an oral Ca-AKG supplement reduces inflammation in humans.

Key findings

  • AKG supported M2 macrophage activation and fatty-acid oxidation.
  • Jmjd3-dependent epigenetic reprogramming was part of the mechanism.
  • The AKG/succinate ratio helped determine inflammatory macrophage phenotype.

What this study can and cannot tell us

  • Mechanistic evidence, not a clinical supplementation trial.
  • Macrophage polarization in experimental systems does not establish whole-body anti-inflammatory efficacy.
  • No commercial Ca-AKG formulation was tested.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology